LYRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LYRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Lyra Therapeutics has the Growth Rank of 0.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
Thank you for viewing the detailed overview of Lyra Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Harlan Waksal | director, officer: Executive Chair | WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042 |
Nbvm Gp, Llc | 10 percent owner | 950 WINTER STREET, SUITE 4600, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Edward T Anderson | director, 10 percent owner | 950 WINTER ST SUITE 4600, WATHAM MA 02451 |
John E Bishop | officer: Chief Technology Officer | 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Richard Nieman | officer: Chief Medical Officer | C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
C Ann Merrifield | director | |
James R Tobin | director | C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Jason Cavalier | officer: Chief Financial Officer | C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472 |
Snyderman Nancy Lynn Md | director | 37 PHEASANT HILL ROAD, PRINCETON NJ 08540 |
Pamela E. Nelson | officer: Senior VP, Regulatory Affairs | C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472 |
Robert E. Richard | officer: SVP of R&D | C10 LYRA THERAPEUTICS, INC., 1480 ALSENAL WAY, WATERTOWN MA 02472 |
Soleus Private Equity Fund I, L.p. | 10 percent owner | C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830 |
Soleus Capital, Llc | 10 percent owner | 104 FIELD POINT ROAD, FLOOR 2, GREENWICH CT 06830 |
Polaris Venture Partners Special Founders' Fund V, L.p. | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
From GuruFocus
By Marketwired • 09-12-2023
By PRNewswire PRNewswire • 08-09-2022
By PRNewswire PRNewswire • 07-07-2022
By Marketwired • 10-16-2023
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 07-09-2022
By sperokesalga sperokesalga • 03-29-2023
By sperokesalga sperokesalga • 05-26-2023
By sperokesalga sperokesalga • 06-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.